Breaking Barriers: Nanomedicine-Based Drug Delivery for Cataract Treatment
Yilin Chen,Zi Ye,Haixu Chen,Zhaohui Li
DOI: https://doi.org/10.2147/ijn.s463679
IF: 7.033
2024-05-07
International Journal of Nanomedicine
Abstract:Yilin Chen, 1, 2 Zi Ye, 1, 2 Haixu Chen, 3 Zhaohui Li 1, 2 1 School of Medicine, Nankai University, Tianjin, People's Republic of China; 2 Senior Department of Ophthalmology, The Chinese People's Liberation Army General Hospital, Beijing, People's Republic of China; 3 Institute of Geriatrics, National Clinical Research Center for Geriatrics Diseases, The Chinese People's Liberation Army General Hospital, Beijing, People's Republic of China Correspondence: Zhaohui Li, Senior Department of Ophthalmology, The Chinese People's Liberation Army General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, People's Republic of China, Email Cataract is a leading cause of blindness globally, and its surgical treatment poses a significant burden on global healthcare. Pharmacologic therapies, including antioxidants and protein aggregation reversal agents, have attracted great attention in the treatment of cataracts in recent years. Due to the anatomical and physiological barriers of the eye, the effectiveness of traditional eye drops for delivering drugs topically to the lens is hindered. The advancements in nanomedicine present novel and promising strategies for addressing challenges in drug delivery to the lens, including the development of nanoparticle formulations that can improve drug penetration into the anterior segment and enable sustained release of medications. This review introduces various cutting-edge drug delivery systems for cataract treatment, highlighting their physicochemical properties and surface engineering for optimal design, thus providing impetus for further innovative research and potential clinical applications of anti-cataract drugs. Keywords: nanomedicine, cataract, ocular barrier, drug delivery system Cataract, the opacification of the normally crystalline lens in the eye, is a leading cause of global blindness, particularly in developing countries. 1 While aging serves as the primary predictor, risk factors encompass diabetes, genetics, trauma, ultraviolet radiation, smoking, and certain medications. 2 The formation is attributed to the abnormal aggregation and decreased solubility of crystalline proteins, leading to lens opacity. 3 Known cataractogenesis involves oxidative stress, osmotic pressure changes, impaired autophagy, abnormal polyol pathways, and abnormal glycosylation. Oxidative stress plays a pivotal role in cataract development, as the lens's antioxidant defenses diminish with age, making it more susceptible to oxidative damage and ultimately triggering cataract. 4 Based on the locations of the opacity, cataracts are categorized into three types: cortical, nuclear and posterior subcapsular cataracts. 2 Currently, the only effective treatment for cataracts is the removal of the opacified lens and the implantation of an intraocular lens. However, cataract surgery is typically performed when the disease is advanced or when the patient's quality of life has been severely compromised. The surgery is invasive and risky, and some patients may experience suboptimal postoperative vision recovery. 5 As the global population ages, the incidence of cataracts is expected to increase. The demand for cataract surgery exceeds limited public health resources, particularly in low-income countries. Studies have estimated that delaying the onset of cataracts for 10 years would halve their incidence. 6 Therefore, finding alternative drug therapies is crucial to reduce the socio-economic burden and improve patients' quality of life. Early intervention is key, and augmenting antioxidant levels can reduce oxidative damage to the lens and suppress protein aggregation. This has been an area of active research for the past two decades, with a surge in studies related to pharmacological interventions for cataract. 7 For instance, lanosterol (LAN), a drug that inhibits protein aggregation, has been demonstrated to decrease cataract severity in ex vivo experiments on animals. 8 Pharmacological treatment for cataract prevention is hindered by the complex anatomical and physiological barriers of the human eye that prevent most ophthalmic drugs from reaching the lens. 9 The traditional method of drug delivery through eye drops has inherent defects, such as poor permeability, uneven distribution, and inadequate bioavailability, which limit the efficacy of drugs. Furthermore, macromolecular drugs, including peptides, proteins, antibodies, and oligonucleotides, face challenges in penetrating the ocular barrier. To improve drug delivery and enhance the ability of drugs to reach the lens, researchers have focused on nano drug delivery systems. To date, numerous nanocarriers have been employed to i -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology